Cancer exosomes are 'micro factories' that aid in tumor growth
MD Anderson News Release 10/23/2014
Tiny nano-sized particles may play a major role in detecting and tracking breast cancer
MD Anderson News Release 10/23/2014
Exosomes, tiny, virus-sized particles released by cancer cells, can bioengineer micro-RNA (miRNA) molecules resulting in tumor growth. They do so with the help of proteins, such as one named Dicer. New research from The University of Texas MD Anderson Cancer Center suggests Dicer may also serve as a biomarker for breast cancer and possibly open up new avenues for diagnosis and treatment. Results from the investigation were published in today’s issue of Cancer Cell.
“Exosomes derived from cells and blood serum of patients with breast cancer, have been shown to initiate tumor growth in non-tumor-forming cells when Dicer and other proteins associated with the development of miRNAs are present,” said Raghu Kalluri, M.D., Ph.D., chair of the department of cancer biology at MD Anderson. “These findings offer opportunities for the development of exosomes-based biomarkers and shed insight into the mechanisms of how cancer spreads.”
Exosomes are small vesicles consisting of DNA, RNA and proteins enclosed in a membranes made up of two lipid layers. They perform specialized functions such as coagulation, intercellular signaling and cell “waste management.” They are shed into bodily fluids forming a source of disease-specific nucleic acids and proteins. Increasingly, exosomes are studied for their potential as both indicators of disease, and as a prospective new treatment approach.
All exosomes contain a cellular stew of smaller components including proteins, messenger RNA (mRNA) and miRNAs. Kalluri’s team reported that breast cancer associated exosomes contain specific miRNAs associated with a multi-protein complex known as RNA-induced silencing complex (RISC).
In addition to RISC, the breast cancer exosomes also house Dicer and two other proteins, AGO2 and TRBP, all of which together provoke tumor growth.
“The role of miRNAs associated with exosomes in cancer progression is largely unknown. Many studies have suggested the presence of miRNAs in exosomes and speculated on their function,” said Kalluri. “We demonstrated that inhibiting the action of Dicer in cancer exosomes significantly impairs tumor growth, raising the possibility that miRNAs in exosomes contributes to cancer progression.”
Kalluri’s study indicated that the interplay between Dicer and its “host” exosome may allow cancer cells to develop an “oncogenic field effect” by manipulating surrounding cells via exosomes. Think of a child blowing a dying dandelion’s spores into the wind where they float over a newly mowed lawn and one can envision how this molecular mixer easily spreads the disease to surrounding tissue.
“These studies reflect the need to evaluate the functional contribution of miRNA machinery in exosomes and their role in tumor progression and metastasis,” said Kalluri.
Kalluri’s MD Anderson team members included Sonia Melo and Hikaru Sugimoto, both postdoctoral fellows in cancer biology; Anthony Lucci , M.D., professor of surgical oncology; Cristina Ivan, gynecologic oncology; and George Calin, M.D., Ph.D., professor of experimental therapeutics. Other collaborating institutions included Beth Israel Deaconess Medical Center and Harvard Medical School in Boston; Bellvitge Biomedical Research Institute, Barcelona, Spain; The Netherlands Cancer Institute, Amsterdam, The Netherlands; and the Centre for Neuroscience and Cell Biology, Coimbra, Portugal.
The study was funded primarily by the Cancer Prevention and Research Institute of Texas. The authors are also supported by the National Science Foundation (EFRI-1240410, CBET-0922876 and CBET-1144025), the National Institutes of Health/National Cancer Institute (R01 EB003472, R01 EB006462, 1UH2TR00943-01, 1R01 CA182905-01, CA-163191, CA155370, CA 151925, DK 081576, and DK 055001), The National Cancer Institute (the Human Frontiers Science Program, the Alan M. Gewirtz Leukemia & Lymphoma Society, the MD Anders Research Trust, The University of Texas System Regents Health Research Scholarship program, and the CCL Global Research Foundation.